Related references
Note: Only part of the references are listed.Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
Eric A. F. Simoes et al.
CLINICAL INFECTIOUS DISEASES (2021)
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial
Steve Cunningham et al.
LANCET RESPIRATORY MEDICINE (2021)
THE NEW WAVE OF VACCINES FOR A KILLER RESPIRATORY VIRUS
Kendall Powell
NATURE (2021)
Epidemiological and virological characteristics of respiratory tract infections in children during COVID-19 outbreak
Yueling Zhu et al.
BMC PEDIATRICS (2021)
Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US
Zhe Zheng et al.
JAMA NETWORK OPEN (2021)
COVID-19 public health measures and respiratory viruses in children in Melbourne
Yara-Natalie Abo et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2021)
Resurgence of Respiratory Syncytial Virus Infections during COVID-19 Pandemic, Tokyo, Japan
Mugen Ujiie et al.
EMERGING INFECTIOUS DISEASES (2021)
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults
Antonios O. Aliprantis et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis
Ting Shi et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected with Respiratory Syncytial Virus
Danielle P. Porter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Co-infections in people with COVID-19: a systematic review and meta-analysis
Louise Lansbury et al.
JOURNAL OF INFECTION (2020)
IMPACT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ON HOST FUNCTIONS: IMPLICATIONS FOR ANTIVIRAL STRATEGIES
MengJie Hu et al.
PHYSIOLOGICAL REVIEWS (2020)
Targeting the Respiratory Syncytial Virus N0-P Complex with Constrained α-Helical Peptides in Cells and Mice
Marie Galloux et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Update on current views and advances on RSV infection (Review)
Ioannis N. Mammas et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2020)
Viperin: An ancient radical SAM enzyme finds its place in modern cellular metabolism and innate immunity
Soumi Ghosh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
M. Pamela Griffin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus
Ksenia V. Kozhikhova et al.
JOURNAL OF MATERIALS CHEMISTRY B (2020)
Partnering for enhanced digital surveillance of influenza-like disease and the effect of antivirals and vaccines (PEDSIDEA)
Barbara Rath et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2019)
Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis
You Li et al.
LANCET GLOBAL HEALTH (2019)
Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
Hayat Caidi et al.
ANTIVIRAL RESEARCH (2018)
Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
Natalia Olchanski et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
M. Pamela Griffin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection
Cristina Capella et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Dirk Roymans et al.
NATURE COMMUNICATIONS (2017)
The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
Antonino Capizzi et al.
ITALIAN JOURNAL OF PEDIATRICS (2017)
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Laurent Detalle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase
Rachel Fearns et al.
ANTIVIRAL RESEARCH (2016)
Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus
Vincent Vanheule et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Viperin protein expression inhibits the late stage of respiratory syncytial virus morphogenesis
Muhammad Raihan Jumat et al.
ANTIVIRAL RESEARCH (2015)
Identification and Characterization of the Binding Site of the Respiratory Syncytial Virus Phosphoprotein to RNA-Free Nucleoprotein
Marie Galloux et al.
JOURNAL OF VIROLOGY (2015)
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial
Katherine L. O'Brien et al.
LANCET INFECTIOUS DISEASES (2015)
Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604
SreeRupa Challa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Structural Analysis of Respiratory Syncytial Virus Reveals the Position of M2-1 between the Matrix Protein and the Ribonucleoprotein Complex
Gabriella Kiss et al.
JOURNAL OF VIROLOGY (2014)
Structure of Nipah virus unassembled nucleoprotein in complex with its viral chaperone
Filip Yabukarsi et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors
Dan Yan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients
J. R. Marcelin et al.
TRANSPLANT INFECTIOUS DISEASE (2014)
A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab′)2 Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice
Seyhan Boyoglu-Barnum et al.
JOURNAL OF VIROLOGY (2013)
The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus
Silke M. Currie et al.
PLOS ONE (2013)
Inhibition of Human Respiratory Syncytial Virus Infectivity by a Dendrimeric Heparan Sulfate-Binding Peptide
Manuela Donalisio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993-2008
Hong Zhou et al.
CLINICAL INFECTIOUS DISEASES (2012)
Respiratory syncytial virus vaccine development
Julia L. Hurwitz
EXPERT REVIEW OF VACCINES (2011)
Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion
Bert Schepens et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease
Timothy F. Feltes et al.
PEDIATRIC RESEARCH (2011)
A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
Michael P. Frogel et al.
JOURNAL OF MANAGED CARE PHARMACY (2010)
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Harish Nair et al.
LANCET (2010)
Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial
Xavier Carbonell-Estrany et al.
PEDIATRICS (2010)
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
Gregory H. Bird et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Treatment of respiratory syncytial virus with palivizumab: a systematic review
Jia Hu et al.
WORLD JOURNAL OF PEDIATRICS (2010)
Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice
Lia M. Haynes et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Peptides That Mimic the Amino-Terminal End of the Rabies Virus Phosphoprotein Have Antiviral Activity
Guillaume Castel et al.
JOURNAL OF VIROLOGY (2009)
Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme DZ1133 in mice
Juan Zhou et al.
VIRUS RESEARCH (2007)
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing
Eric A. F. Simoes et al.
JOURNAL OF PEDIATRICS (2007)
Modular α-helical mimetics with antiviral activity against respiratory syncitial virus
Nicholas E. Shepherd et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model:: Time versus potency
A Mejías et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers
PJ Budge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3
MK Pastey et al.
NATURE MEDICINE (2000)